News

Get Alerts by Email

Sep 8, 2016

Galmed Pharmaceuticals Announces the Appointment of Dr. Liat Hayardeny, Ph.D. MBA, as Chief Scientific Officer

- New CSO Position Aimed Towards Expanding Therapeutic Potential of Aramchol™ -

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...
- Photos 1
Aug 3, 2016

Galmed Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

- Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT -

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...
- Photos 1
Aug 1, 2016

Galmed Pharmaceuticals Announces the Appointment of Professor Ran Oren, M.D., as Chief Medical Officer

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...
- Photos 1
Jul 28, 2016

Galmed Pharmaceuticals and SAMIL Pharm Sign a License Agreement for the Commercialization of Aramchol™ in Korea

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...
- Photos 1
Jul 27, 2016

Galmed Pharmaceuticals Second Quarter 2016 Conference Call and Webcast Scheduled for Wednesday, August 3rd, 2016

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...
- Photos 1
Jun 30, 2016

Galmed Pharmaceuticals and Weizmann Institute of Science to enter a research collaboration agreement to assess Aramchol™ effects on microbiome

Collaboration will allow deeper understanding of Aramchol's mechanism of action and could provide insights for new therapeutic strategies as well as the development of NASH noninvasive diagnostic and therapy prognostic tools

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...
- Photos 1
Jun 7, 2016

Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...
- Photos 1
Jun 1, 2016

Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...
- Photos 1
May 16, 2016

Galmed Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update

- Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT -

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...
- Photos 1
May 9, 2016

Galmed Pharmaceuticals First Quarter 2016 Conference Call and Webcast Scheduled for Monday, May 16th, 2016

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...

Show per page